Ingmar Bruns - 06 Feb 2026 Form 4 Insider Report for Zentalis Pharmaceuticals, Inc. (ZNTL)

Role: Chief Medical Officer
Signature: /s/ James B. Bucher, attorney-in-fact for Ingmar Bruns
Issuer symbol: ZNTL
Transactions as of: 06 Feb 2026
Net transactions value: -$7,998
Form type: 4
Filing time: 10 Feb 2026, 21:10:49 UTC
Previous filing: 09 Jan 2026
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
Bruns Ingmar	Chief Medical Officer	C/O ZENTALIS PHARMACEUTICALS, INC., 10275 SCIENCE CENTER DRIVE, SUITE 200, SAN DIEGO	/s/ James B. Bucher, attorney-in-fact for Ingmar Bruns	10 Feb 2026	0001838041

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	ZNTL	Common Stock	Sale	$7,197	-2,962	-8.1%	$2.43	33,667	06 Feb 2026	Direct	F1
transaction	ZNTL	Common Stock	Sale	$802	-335	-1%	$2.39	33,332	09 Feb 2026	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	This sale was made automatically by the Issuer to cover tax withholding obligations in connection with the vesting and settlement of restricted stock units previously granted to the Reporting Person.